Biomarin pharmaceutical inc. is an american biotechnology company headquartered in san rafael, california. it has offices and facilities in the united states, south america, asia, and europe. biomarin's core business and research is in enzyme replacement therapies (erts). biomarin was the first company to provide therapeutics for mucopolysaccharidosis type i (mps i), by manufacturing laronidase (aldurazyme, commercialized by genzyme corporation). biomarin was also the first company to provide therapeutics for phenylketonuria (pku).
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of innovative pharmaceuticals for serious diseases and medical conditions. It operates its business through one segment, the biopharmaceutical development and commercialization segment. Its company's products include Naglazyme, Kuvan, Aldurazyme, Firdapse and VIMIZIM. The company was founded on March 21, 1997 and is headquartered in Novato, CA.
According to Forbes.